EUVIMEDOpdag EUVIMED
Systematische ÜbersichtNetzwerk-Metaanalyse

Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials

Evaluation von blutzuckersenkenden Medikamenten bei älteren Menschen: umfassende systematische Übersicht und Netzwerk-Metaanalyse randomisierter kontrollierter Studien

Ssu-Yu Pan iD, En-Lin Su, Chi-Jung Huang, Shao-Yuan Chuang, Chern-En Chiang, Chen-Huan Chen, Hao-Min Cheng iD

Age and Ageing · 2024-08-06 · 53 (8)

DOI: 10.1093/ageing/afae175 ↗

Auf einen Blick

22 Studien mit 41 654 Teilnehmenden: GLP-1RAs senkten MACE und Körpergewicht, SGLT2-Inhibitoren Herzinsuffizienz‑Hospitalisierungen, Nierenendpunkte und Körpergewicht.

Fragestellung

Welche Vor- und Nachteile haben verschiedene blutzuckersenkende Medikamente bei Erwachsenen ab 65 Jahren mit T2DM?

Methode

Netzwerk-Metaanalyse randomisierter kontrollierter Studien; Suche in PubMed, Cochrane CENTRAL und Embase bis 23. September 2023; Bewertung mit Cochrane RoB 2.0.

Ergebnisse

22 Studien mit 41 654 Teilnehmenden. GLP-1RAs: RR für MACE 0,83 (95 %-KI 0,71–0,97), MD Körpergewicht −3,87 kg (95 %-KI −5,54 bis −2,21). SGLT2-Inhibitoren: RR Herzinsuffizienz-Hospitalisierung 0,66 (95 %-KI 0,57–0,77), RR renaler Endpunkt 0,69 (95 %-KI 0,53–0,89), MD −1,85 kg (95 %-KI −2,42 bis −1,27). SU erhöhten Hypoglykämien.

Schlussfolgerung der Autor:innen

Neuere blutzuckersenkende Medikamente mit Nutzen, der die Risiken überwiegt, sollten bei älteren Patient:innen mit Diabetes priorisiert werden.

Kernaussagen

  • GLP-1RAs senkten MACE und Körpergewicht.
  • SGLT2-Inhibitoren senkten Herzinsuffizienz- und renale Endpunkte.
  • SU erhöhten das Risiko für Hypoglykämien.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Systematische Übersicht in Age and Ageing, published online on 2024-08-13. Written by Ssu-Yu Pan and 6 co-authors. Institution: Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Randomized Controlled Trials as Topic. Cited 23 times so far (Crossref); 63 references. Funded by: Ministry of Health and Welfare, Ministry of Science and Technology, National Yang Ming Chiao Tung University.

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Type 2 diabetes mellitus (T2DM) is increasingly being diagnosed in older adults. Our objective is to assess the advantages and potential drawbacks of different glucose-lowering medications in this specific population.

Methods

A network meta-analysis was conducted to identify randomized controlled trials that examined patient-centered outcomes in adults aged ≥65 years with T2DM. We searched PubMed, Cochrane CENTRAL, and Embase up to September 23, 2023. Quality of eligible studies were assessed using the Cochrane RoB 2.0 tool.

Results

A total of 22 trials that involved 41 654 participants were included, incorporating sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors, metformin, sulfonylureas (SU) and acarbose. Our findings reveal that GLP-1RAs reduce the risk of major adverse cardiovascular events (risk ratio [RR], 0.83; 95% confidence interval [CI], 0.71 to 0.97) and body weight (mean difference [MD], −3.87 kg; 95% CI, −5.54 to −2.21). SGLT2 inhibitors prevent hospitalization for heart failure (RR, 0.66; 95% CI, 0.57 to 0.77), renal composite outcome (RR, 0.69; 95% CI, 0.53 to 0.89), and reduce body weights (MD, −1.85 kg; 95% CI, −2.42 to −1.27). SU treatment increases the risk of any hypoglycaemia (RR, 4.19; 95% CI, 3.52 to 4.99) and severe hypoglycaemia (RR, 7.06; 95% CI, 3.03 to 16.43). GLP-1RAs, SGLT2 inhibitors, metformin, SU and DPP-4 inhibitors are effective in reducing glycaemic parameters. Notably, the number of treatments needed decreases in most cases as age increases.

Conclusions

Novel glucose-lowering medications with benefits that outweigh risks should be prioritized for older patients with diabetes.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsRandomized Controlled Trials as TopicAgedFemaleHumansMaleAge FactorsBlood GlucoseTreatment Outcome

Author keywords

agingcardiovascular diseasedipeptidyl peptidase-4 (DPP-4)glucagon-like peptide-1 receptor agonists (GLP-1RAs)glucose-lowering medicationheart failureolder peoplerenal diseasesodium-glucose cotransporter-2 (SGLT2) inhibitorssystematic reviewtype 2 diabetes

Substances

Blood GlucoseHypoglycemic Agents

Authors and institutions

  • Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Population Health Science, National Health Research Institute, Miaoli, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan.
  • General Clinical Research Centre, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Public Health and Community Medicine Research Centre, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan.

ORCID profiles: Ssu-Yu Pan, Hao-Min Cheng

Funding

  • Ministry of Health and Welfare
  • Ministry of Science and Technology
  • National Yang Ming Chiao Tung University

Cite

APA

Pan, S. Y., Su, E. L., Huang, C. J., Chuang, S. Y., Chiang, C. E., Chen, C. H., & Cheng, H. M. (2024). Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials. Age and Ageing, 53(8). https://doi.org/10.1093/ageing/afae175

Vancouver

Pan SY, Su EL, Huang CJ, Chuang SY, Chiang CE, Chen CH, et al. Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials. Age and Ageing. 2024;53(8). doi:10.1093/ageing/afae175

BibTeX
@article{Pan2024,
  author = {Pan, Ssu-Yu and Su, En-Lin and Huang, Chi-Jung and Chuang, Shao-Yuan and Chiang, Chern-En and Chen, Chen-Huan and Cheng, Hao-Min},
  title = {Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials},
  journal = {Age and Ageing},
  year = {2024},
  volume = {53},
  number = {8},
  doi = {10.1093/ageing/afae175}
}
Start for free →